To evaluate changes in photophobia using the Turkish version of Utah Photophobia Symptom Impact Scale–12 (UPSIS-12) in patients with episodic and chronic migraine treated with galcanezumab, and to examine the relationship between photophobia, migraine outcomes, disability, and treatment response.
Key Findings:
77 patients enrolled; 47 completed the study.
Monthly headache days decreased from a median of 15 to 4 days by month 3 (p < 0.001).
74.5% of patients were classified as responders (≥50% reduction).
UPSIS-12 scores declined significantly (median 22.6%; p < 0.001).
Responders showed a notable reduction in ictal photophobia (p = 0.010).
Improvements were also observed in ictal phonophobia, osmophobia, and cutaneous allodynia.
Headache intensity, attack duration, acute medication use, disability, and comorbid depression and anxiety scores improved.
Interpretation:
Galcanezumab was associated with reductions in migraine frequency, severity, disability, psychological comorbidities, and ictal photophobia.
Limitations:
Retrospective design may introduce bias.
Small sample size limits generalizability.
Short follow-up period may not capture long-term effects.
Conclusion:
Galcanezumab treatment is associated with reductions in photophobia and other migraine-related symptoms.
